(NASDAQ: NVCT) Nuvectis Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Nuvectis Pharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NVCT's revenue for 2027 to be $1,228,998,472, with the lowest NVCT revenue forecast at $1,228,998,472, and the highest NVCT revenue forecast at $1,228,998,472. On average, 2 Wall Street analysts forecast NVCT's revenue for 2028 to be $1,252,751,231, with the lowest NVCT revenue forecast at $40,178,796, and the highest NVCT revenue forecast at $2,465,323,666.
In 2029, NVCT is forecast to generate $3,729,064,979 in revenue, with the lowest revenue forecast at $3,729,064,979 and the highest revenue forecast at $3,729,064,979.